Ramsay Stattman Vela & Price Inc. Sells 8,218 Shares of Abbott Laboratories $ABT

Posted by Stanley Muller on Jul 10th, 2026

Ramsay Stattman Vela & Price Inc. cut its position in Abbott Laboratories (NYSE:ABT – Free Report) by 7.4% during the first quarter, Holdings Channel.com reports. The institutional investor owned 102,369 shares of the healthcare product maker’s stock after selling 8,218 shares during the quarter. Abbott Laboratories accounts for 2.1% of Ramsay Stattman Vela & Price Inc.’s investment portfolio, making the stock its 18th largest holding. Ramsay Stattman Vela & Price Inc.’s holdings in Abbott Laboratories were worth $10,510,000 at the end of the most recent quarter.

Several other hedge funds also recently modified their holdings of the company. GreatBanc Trust CO raised its stake in shares of Abbott Laboratories by 3.4% in the first quarter. GreatBanc Trust CO now owns 3,790 shares of the healthcare product maker’s stock valued at $389,000 after acquiring an additional 125 shares during the last quarter. Meadow Creek Wealth Advisors LLC grew its position in Abbott Laboratories by 12.8% during the 1st quarter. Meadow Creek Wealth Advisors LLC now owns 4,141 shares of the healthcare product maker’s stock worth $425,000 after acquiring an additional 471 shares during the last quarter. Peterson Wealth Services increased its holdings in Abbott Laboratories by 22.8% during the 1st quarter. Peterson Wealth Services now owns 2,023 shares of the healthcare product maker’s stock valued at $208,000 after purchasing an additional 376 shares in the last quarter. Griffin Asset Management Inc. increased its holdings in Abbott Laboratories by 10.1% during the 1st quarter. Griffin Asset Management Inc. now owns 65,442 shares of the healthcare product maker’s stock valued at $6,719,000 after purchasing an additional 6,023 shares in the last quarter. Finally, Main Street Research LLC raised its position in Abbott Laboratories by 5.6% in the 1st quarter. Main Street Research LLC now owns 3,859 shares of the healthcare product maker’s stock valued at $396,000 after purchasing an additional 205 shares during the last quarter. Institutional investors and hedge funds own 75.18% of the company’s stock.

Insider Activity

In related news, Director Daniel J. Starks bought 10,000 shares of Abbott Laboratories stock in a transaction on Monday, April 27th. The shares were purchased at an average price of $92.65 per share, for a total transaction of $926,500.00. Following the completion of the acquisition, the director owned 6,751,103 shares in the company, valued at approximately $625,489,692.95. This represents a 0.15% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Philip P. Boudreau bought 2,200 shares of the firm’s stock in a transaction dated Thursday, April 23rd. The shares were bought at an average price of $91.50 per share, with a total value of $201,300.00. Following the completion of the transaction, the chief financial officer directly owned 2,200 shares in the company, valued at approximately $201,300. This trade represents a ∞ increase in their position. The disclosure for this purchase is available in the SEC filing. Corporate insiders own 0.46% of the company’s stock.

Analysts Set New Price Targets

Several analysts have recently commented on the company. Mizuho decreased their target price on Abbott Laboratories from $125.00 to $115.00 and set a “neutral” rating on the stock in a report on Friday, April 17th. Daiwa Securities Group cut Abbott Laboratories from an “outperform” rating to a “neutral” rating and set a $92.00 price target for the company. in a report on Wednesday, April 22nd. Barclays decreased their price objective on shares of Abbott Laboratories from $144.00 to $143.00 and set an “overweight” rating on the stock in a report on Monday, April 20th. Sanford C. Bernstein lowered their price objective on shares of Abbott Laboratories from $125.00 to $110.00 and set an “outperform” rating for the company in a research report on Friday, April 17th. Finally, Weiss Ratings raised shares of Abbott Laboratories from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Tuesday. Three equities research analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and five have given a Hold rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $118.42.

Check Out Our Latest Research Report on Abbott Laboratories

Abbott Laboratories Price Performance

Shares of ABT stock opened at $94.25 on Friday. The firm’s 50 day moving average price is $89.16 and its two-hundred day moving average price is $103.31. The company has a debt-to-equity ratio of 0.56, a quick ratio of 1.01 and a current ratio of 1.39. Abbott Laboratories has a 52-week low of $81.97 and a 52-week high of $137.49. The stock has a market cap of $164.16 billion, a PE ratio of 26.40, a PEG ratio of 1.64 and a beta of 0.61.

Abbott Laboratories (NYSE:ABT – Get Free Report) last issued its earnings results on Thursday, April 16th. The healthcare product maker reported $1.15 EPS for the quarter, beating the consensus estimate of $1.14 by $0.01. The company had revenue of $11.16 billion during the quarter, compared to analysts’ expectations of $10.99 billion. Abbott Laboratories had a net margin of 13.90% and a return on equity of 17.62%. The business’s revenue for the quarter was up 7.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.09 EPS. Abbott Laboratories has set its FY 2026 guidance at 5.380-5.580 EPS and its Q2 2026 guidance at 1.250-1.310 EPS. As a group, analysts forecast that Abbott Laboratories will post 5.48 EPS for the current year.

Abbott Laboratories Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, August 17th. Investors of record on Wednesday, July 15th will be issued a $0.63 dividend. This represents a $2.52 dividend on an annualized basis and a yield of 2.7%. The ex-dividend date is Wednesday, July 15th. Abbott Laboratories’s dividend payout ratio is currently 70.59%.

Abbott Laboratories Profile

(Free Report)

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.